Finnish Institute for Molecular Medicine

Source: Wikipedia, the free encyclopedia.

The Institute for Molecular Medicine Finland (FIMM) is an international research institute which investigates the molecular mechanism of diseases by methods involving genetics and medical systems biology. The research combines technology and high-level research with unique patients and biobank materials. The aim of FIMM is to transfer research data to medical use in healthcare, i.e. improving and promoting personalised medicine.

FiMM is member of EU-LIFE, an alliance of leading life sciences research centres in Europe.[1]

Organisation

FIMM was founded in 2007 as a joint research institute of University of Helsinki, the Hospital District of Helsinki and Uusimaa (HUS), Finnish Institute for Health and Welfare (THL) and the VTT Technical Research Centre of Finland.[2] In 2017, FIMM became an independent operational unit of the new section of University of Helsinki, the Helsinki Institute of Life Science (HiLIFE). FIMM is located in the Biomedicum Helsinki research cluster.[3]

The current director of FIMM is

SciLifeLab.[6][7] Professor Eero Saksela
acted as a project leader during the FIMM establishment phase (2007).

References

  1. ^ "Our members". EU-LIFE.
  2. ^ "Molekyylilääketieteen instituutille johtaja". Yliopisto. No. 10. 2007. p. 7.
  3. ^ "Helsinki Institute of life Science (HiLIFE)". Helsingin yliopisto, helsinki.fi.
  4. ^ Mari Kaunisto (2018-02-07). "Mark Daly nimitetty FIMMin uudeksi johtajaksi". FIMM. Retrieved 2019-06-05.
  5. ^ "Suomen molekyylilääketieteen instituutin uudeksi johtajaksi akatemiaprofessori Jaakko Kaprio". FIMM. 2015-09-07. Retrieved 2017-03-30.
  6. ^ "Suomen molekyylilääketieteen instituutin johtajaksi akatemiaprofessori Olli Kallioniemi". Biomedicum. Retrieved 2013-09-27.
  7. ^ "Olli Kallioniemi is the new Director for SciLifeLab". Karolinska Institutet, ki.se. Archived from the original on 2016-11-12. Retrieved 2020-11-06.

Further reading

External links